Role of Cell Block and Cytology in Patients with Known Cancer
In patients with known malignancy, both cell block preparation and conventional cytology smears should be performed together on fluid samples or fine-needle aspirates, as the combined approach increases diagnostic sensitivity by 13-17% compared to either method alone and enables critical ancillary testing including immunohistochemistry for determining primary tumor site and molecular analysis for treatment selection. 1, 2, 3
Complementary Diagnostic Value
Superior Performance with Combined Approach
- Cell block and cytology smears detect different positive cases: 11% of samples negative on cytology smears show malignant cells on cell blocks, while 15% of negative cell blocks are positive on smear slides 2
- The combined technique yields 13% more malignant diagnoses than smears alone 3
- In malignant pleural effusions specifically, combining liquid-based cytology with cell block increases sensitivity from 81.3% (cytology alone) to 98.3% 1
- Using both methods together achieves 100% sensitivity and 100% specificity when integrated with CEA immunostaining 1
Distinct Advantages of Each Method
Cell Block Advantages:
- Provides superior architectural preservation showing acini, papillae, cell balls, and proliferation spheres that are critical for determining primary tumor site 3
- Enables immunohistochemistry panels that can identify the primary site in 83.3% of metastatic cases 4, 3
- Allows molecular analysis including next-generation sequencing platforms required for targeted therapy selection 5
- Achieves 94.3% sensitivity compared to 81.3% for liquid-based cytology alone 1
Cytology Smear Advantages:
- Better preserves individual cell morphology and nuclear details 2, 3
- Provides immediate assessment capability when rapid on-site evaluation (ROSE) is available 5
- Performs better in samples with low cellularity where cell block preparation may be suboptimal 2
Practical Implementation for Known Cancer Patients
Sample Collection Requirements
- Submit 25-50 mL of pleural or peritoneal fluid for optimal diagnostic yield when malignancy is suspected 6, 7
- Divide specimen to prepare both conventional smears and cell block simultaneously 8, 2
- For EBUS-TBNA samples in known cancer patients, discuss with cytopathology whether formalin-fixed paraffin-embedded blocks are needed for specific molecular platforms 5
Ancillary Testing Capabilities
- Immunohistochemistry on cell blocks enables:
- Differentiation of primary versus metastatic disease 4
- Identification of primary tumor site in metastatic adenocarcinomas (e.g., MOC-31 and WT-1 for ovarian versus other primaries) 4
- Tumor marker analysis such as CEA immunostaining, which when combined with cell block achieves 100% diagnostic accuracy 1
- Molecular testing requires cell block preparation for most next-generation sequencing platforms and research trial enrollment 5
Critical Technical Considerations
When Cell Block May Be Suboptimal
- Samples with low red blood cell and/or white blood cell counts more frequently result in inadequate cell block preparations 2
- In these cases, cytology smears become particularly valuable as they may capture diagnostic cells that cell blocks miss 2
Processing Recommendations
- Process cytology samples within 24-48 hours for optimal cell morphology, though refrigeration is acceptable if immediate processing is impossible 9
- Coordinate with local cytopathology department regarding preferred collection media, as certain molecular platforms may require specific fixatives 5
Common Pitfalls to Avoid
- Never rely on cytology smears alone in patients with known cancer, as this misses 11% of positive cases that only cell blocks detect 2
- Never rely on cell block alone, as this misses 15% of positive cases that only smears detect 2
- Do not assume adequate sample volume—always collect 25-50 mL minimum for fluid samples to maximize both cytology and cell block yield 6, 7
- Do not skip immunohistochemistry when the primary site is unknown, as IHC panels on cell blocks can identify the primary in over 80% of metastatic cases 4, 3